tradmap

SGP Earnings SpyGlass Pharma, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$18 -$9 $0 2024 2025
EPS
Net income (annual)
-$40M -$20M $0 2024 2025
Net income
Return on equity (annual)
0% 24% 48% 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$8 -$4 $0 Q1 '25 Q2 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$20M -$10M $0 Q1 '25 Q2 '25 Q1 '26 Q2 '26
Net income
Return on equity (quarterly)
-9% 2% 13% 0% Q1 '25 Q2 '25 Q1 '26 Q2 '26
ROE

Reported EPS history

1–6 of 6
Q2 20262026-06-30-1.262026-08-0610-Q
Q1 20262026-03-31-0.692026-05-1410-Q
FY 20252025-12-31-17.982026-03-2610-K
Q2 20262025-06-30-7.762026-08-0610-Q
Q1 20262025-03-31-3.962026-05-1410-Q
FY 20252024-12-31-16.312026-03-2610-K

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.